Genomic diagnosis for children with intellectual disability and/or developmental delay
Kevin M. BowlingiD, Michelle L. ThompsoniD, Michelle D. Amaral, Candice R. FinnilaiD, Susan M. HiattiD, Krysta L. EngeliD, J. Nicholas CochraniD, Kyle Bertram BrothersiD, Kelly M. EastiD, David E. Gray, Whitley V. Kelley, Neil E. Lamb, Edward J. Lose, Carla A. RichiD, Shirley Simmons, Jana Whittle, Benjamin T. Weaver, Amy S. Nesmith, R MyersiD, Gregory S. BarshiD, Elizabeth Martina BebiniD, Gregory M. CooperiD
Abstract
BackgroundDevelopmental disabilities have diverse genetic causes that must be identified to facilitate precise diagnoses. We describe genomic data from 371 affected individuals, 309 of which were sequenced as proband-parent trios.\n\nMethodsWhole exome sequences (WES) were generated for 365 individuals (127 affected) and whole genome sequences (WGS) were generated for 612 individuals (244 affected).\n\nResultsPathogenic or likely pathogenic variants were found in 100 individuals (27%), with variants of uncertain significance in an additional 42 (11.3%). We found that a family history of neurological disease, especially the presence of an affected 1st degree relative, reduces the pathogenic/likely pathogenic variant identification rate, reflecting both the disease relevance and ease of interpretation of de novo variants. We also found that improvements to genetic knowledge facilitated interpretation changes in many cases. Through systematic reanalyses we have thus far reclassified 15 variants, with 11.3% of families who initially were found to harbor a VUS, and 4.7% of families with a negative result, eventually found to harbor a pathogenic or likely pathogenic variant. To further such progress, the data described here are being shared through ClinVar, GeneMatcher, and dbGAP.\n\nConclusionOur data strongly support the value of large-scale sequencing, especially WGS within proband-parent trios, as both an effective first-choice diagnostic tool and means to advance clinical and research progress related to pediatric neurological disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 273
- FWCI
- 14.67
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comprehensive genetic analysis by whole exome sequencing in 352 Korean pediatric patients with unknown neurodevelopmental disorders
Youngha Lee, Jin Sook Lee, … Jong‐Hee Chae·bioRxiv·Nov 18, 2018
- A nationwide prospective randomized trial for diagnosing developmental disorders demonstrates genome sequencing outperforms standard of care.
Mathilde Geysens, Erika L. Souche, … Joris Robert Vermeesch·medRxiv·Oct 18, 2025
- Optimising diagnostic yield in highly penetrant genomic disease
Caroline Fiona Wright, Patrick H. Campbell, … Helen V. Firth·medRxiv·Jul 25, 2022
- Genomic sequencing identifies secondary findings in a cohort of parent study participants
Michelle L. Thompson, Candice R. Finnila, … Gregory M. Cooper·Genetics in MedicinePeer-reviewed·Apr 12, 2018
- Genome sequencing boosts diagnostic yield for the developmental and epileptic encephalopathies
Jacob E. Munro, Harshini Thiyagarajah, … Michael S. Hildebrand·medRxiv·Apr 28, 2026
- Whole Exome Sequencing in Neurogenetic Diagnostic Odysseys: An Argentinian Experience
M Córdoba, SA Rodriguez-Quiroga, … MA Kauffman·bioRxiv·Jun 23, 2016